Article List
List all articles in the database by descending article_id
GET /articles/
{ "count": 18780, "next": "http://api.gregory-ms.com/articles/?page=2", "previous": null, "results": [ { "article_id": 1391899, "title": "Design, Radiosynthesis, and Evaluation of New Fluorinated Analogs of MeDAS for Myelin PET Imaging", "summary": "<div><p>J Med Chem. 2023 Jun 8. doi: 10.1021/acs.jmedchem.3c00325. Online ahead of print.</p><p><b>ABSTRACT</b></p><p>Positron emission tomography (PET) imaging of the myelin sheath is a powerful tool to investigate multiple sclerosis, monitor its evolution, and support drug development. Radiotracers based on <i>N,N</i>-dimethylaminostilbene (MeDAS) fluorinated analogs have been designed for myelin PET imaging but were never translated to humans. We have synthesized three original fluorinated analogs of MeDAS with low metabolic rates for which binding to myelin in a healthy rat brain was demonstrated by fluorescence microscopy. A tosyl precursor was synthesized for the lead compound PEGMeDAS and automated fluorine-18 radiolabeling afforded [<sup>18</sup>F]PEGMeDAS in 25 ± 5% radiochemical yield and 102 ± 15 GBq/μmol molar activity. Biodistribution in healthy rats demonstrated the brain penetration with low penetration of radiometabolites. However, <i>E</i> to <i>Z</i> isomerization observed in plasma hampers further investigations of this family of molecules and requires complementary data on the <i>in vivo</i> behavior of the <i>Z</i> isomer.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37288728/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20230608134016&v=2.17.9.post6+86293ac\">37288728</a> | DOI:<a href=\"https://doi.org/10.1021/acs.jmedchem.3c00325\">10.1021/acs.jmedchem.3c00325</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/37288728/?fc=20210216052009&ff=20230608134016&v=2.17.9.post6+86293ac", "published_date": "2023-06-08T10:00:00Z", "source": "PubMed", "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "discovery_date": "2023-06-08T17:40:20.308146Z", "noun_phrases": [ "Design", "Radiosynthesis", "Evaluation", "New Fluorinated Analogs", "MeDAS", "Myelin PET Imaging" ], "doi": "10.1021/acs.jmedchem.3c00325", "access": "restricted", "takeaways": "PET imaging of the myelin sheath is a powerful tool to investigate multiple sclerosis, monitor its evolution and support drug development. Radiotracers based on N,N-dimethylaminostilbene (MeDAS) fluorinated analogs have been designed for myelin PET imaging but were never translated to humans. They have synthesized three original", "categories": [] }, { "article_id": 1391898, "title": "Autosomal dominant genodermatoses in adults being heralded by superimposed skin lesions in children", "summary": "<div><p>Am J Med Genet C Semin Med Genet. 2023 Jun 8. doi: 10.1002/ajmg.c.32055. Online ahead of print.</p><p><b>ABSTRACT</b></p><p>In autosomal dominant skin disorders, pronounced mosaic involvement may sometimes occur in the neonate, originating in a heterozygous embryo from early loss of heterozygosity, probably during the first week after fertilization. In biallelic phenotypes, such overlaying mosaic involvement may coexist with disseminated mosaicism, for example, in neurofibromatosis or tuberous sclerosis. In other phenotypes, however, classical nonsegmental involvement tends to appear much later, which is why the superimposed mosaic is a heralding feature. In Brooke-Spiegler syndrome (eccrine cylindromatosis), a large pedigree documented a 5-year-old boy with multiple, congenital small eccrine cylindromas along the lines of Blaschko. Disseminated cylindromas were absent because they usually appear in adulthood. ̶ In Hornstein-Knickenberg syndrome, an affected woman had an 8-year-old son with a nevus comedonicus-like lesion exemplifying a forerunner of the syndrome. (\"Birt-Hogg-Dubé syndrome\" represents a nonsyndromic type of hereditary perifollicular fibromas.) In glomangiomatosis, neonatal superimposed mosaicism is a heralding feature because disseminated lesions appear during puberty or adulthood. Linear porokeratosis is a harbinger of disseminated porokeratosis that develops 30 or 40 years later. ̶ Cases of superimposed linear Darier disease were forerunners of nonsegmental manifestation. ̶ In a case of Hailey-Hailey disease, neonatal mosaic lesions heralded nonsegmental involvement that began 22 years later.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37288730/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20230608134016&v=2.17.9.post6+86293ac\">37288730</a> | DOI:<a href=\"https://doi.org/10.1002/ajmg.c.32055\">10.1002/ajmg.c.32055</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/37288730/?fc=20210216052009&ff=20230608134016&v=2.17.9.post6+86293ac", "published_date": "2023-06-08T10:00:00Z", "source": "PubMed", "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "discovery_date": "2023-06-08T17:40:19.564244Z", "noun_phrases": [ "Autosomal dominant genodermatoses", "adults", "superimposed skin lesions", "children" ], "doi": "10.1002/ajmg.c.32055", "access": "restricted", "takeaways": "Mosaic involvement in autosomal dominant skin disorders may sometimes occur in the neonate. Disseminated cylindromas usually appear in adulthood. Neonatal superimposed mosaicism is a heralding feature.", "categories": [] }, { "article_id": 1391897, "title": "Neurodegeneration in the retina of motoneuron diseases: a longitudinal study in amyotrophic lateral sclerosis and Kennedy's disease", "summary": "<div><p>J Neurol. 2023 Jun 8. doi: 10.1007/s00415-023-11802-2. Online ahead of print.</p><p><b>ABSTRACT</b></p><p>BACKGROUND: To what extent retinal atrophy in neurodegenerative diseases reflects the severity and/or the chronicity of brain pathology or is a local independent phenomenon remains to be clarified. Moreover, whether retinal atrophy has a clinical (diagnostic and prognostic) value in these diseases remains unclear.</p><p>OBJECTIVE: To add light on the pathological significance and clinical value of retinal atrophy in patients with amyotrophic lateral sclerosis (ALS) and Kennedy's disease (KD).</p><p>METHODS: Thirty-five ALS, thirty-seven KD, and forty-nine age-matched healthy controls (HC) were included in a one-year longitudinal study. Spectrum-domain optical coherence tomography (OCT) was performed at study entry (T0) and after 12 months (T1). Disease duration and functional rating scale (FRS) for ALS and KD patients were correlated to retinal thicknesses.</p><p>RESULTS: Compared to HC, peripapillary retinal nerve fiber layer (pRNFL) thickness was significantly thinner in both ALS (p = 0.034) and KD (p = 0.003). pRNFL was thinner in KD compared to ALS, but the difference was not significant. In KD, pRNFL atrophy significantly correlated with both disease severity (r = 0.296, p = 0.035) and disease duration (r = - 0.308, p = 0.013) while no significant correlation was found in ALS (disease severity: r = 0.147, p = 0.238; disease duration: r = - 0.093, p = 0.459). During the follow-up, pRNFL thickness remained stable in KD while significantly decreased in ALS (p = 0.043).</p><p>CONCLUSIONS: Our study provides evidence of retinal atrophy in both ALS and KD and suggests that retinal thinning is a primary local phenomenon in motoneuron diseases. The clinical value of pRNFL atrophy in KD is worthy of further investigation.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37289322/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20230608134016&v=2.17.9.post6+86293ac\">37289322</a> | DOI:<a href=\"https://doi.org/10.1007/s00415-023-11802-2\">10.1007/s00415-023-11802-2</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/37289322/?fc=20210216052009&ff=20230608134016&v=2.17.9.post6+86293ac", "published_date": "2023-06-08T10:00:00Z", "source": "PubMed", "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "discovery_date": "2023-06-08T17:40:18.835302Z", "noun_phrases": [ "Neurodegeneration", "the retina", "motoneuron diseases", "a longitudinal study", "amyotrophic lateral sclerosis", "Kennedy's disease" ], "doi": "10.1007/s00415-023-11802-2", "access": "restricted", "takeaways": "There is evidence of retinal atrophy in patients with amyotrophic lateral sclerosis (ALS) and Kennedy's disease (KD) in both ALS and KD.", "categories": [] }, { "article_id": 1391896, "title": "Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE Study", "summary": "<div><p>Neurol Ther. 2023 Jun 8. doi: 10.1007/s40120-023-00497-2. Online ahead of print.</p><p><b>ABSTRACT</b></p><p>INTRODUCTION: Inconvenient administration and side effects of some disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) can deter adherence. We evaluated treatment satisfaction with cladribine tablets (CladT) for RMS in the Arabian Gulf.</p><p>METHODS: This was a non-interventional, multicentre, prospective observational study in non-pregnant/lactating adults (aged ≥ 18 years) with RMS eligible for 1st treatment with CladT (EU labelling). The primary outcome was overall treatment satisfaction at 6 months (Treatment Satisfaction Questionnaire for Medication [TSQM]-14, v. 1.4), Global Satisfaction subscale. Secondary endpoints were TSQM-14 scores for convenience, satisfaction with side effects and satisfaction with effectiveness. Patients provided written informed consent.</p><p>RESULTS: Of 63 patients screened, 58 received CladT and 55 completed the study. Mean age was 33 ± 9 years; mean weight 73 ± 17 kg; 31% male/69% female; mostly from the United Arab Emirates (52%) or Kuwait (30%). All had RMS (mean 0.9 ± 1.1 relapses in the past year), mean Expanded Disability Status Scale (EDSS) 1.4 ± 1.2; 36% were DMT-naïve. Mean [95% CI] score was high for overall treatment satisfaction (77.8 [73.0-82.6]), ease of use (87.4 [83.7-91.0]), tolerability (94.2 [91.0-97.3]) and effectiveness (76.2 [71.6-80.7]). Scores were similar irrespective of DMT history, age, gender, relapse history or EDSS. No relapses or serious treatment-emergent adverse events (TEAE) occurred. Two severe TEAE occurred (fatigue, headache) and 16% reported lymphopenia (two cases of grade 3 lymphopenia). Absolute lymphocyte counts at baseline and 6 months were 2.2 ± 0.8 × 10<sup>9</sup>/L and 1.3 ± 0.3 × 10<sup>9</sup>/L, respectively.</p><p>CONCLUSIONS: Treatment satisfaction, ease of use, tolerability and patient-perceived effectiveness for CladT were high, irrespective of baseline demographics, disease characteristics and prior treatment.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37289421/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20230608134016&v=2.17.9.post6+86293ac\">37289421</a> | DOI:<a href=\"https://doi.org/10.1007/s40120-023-00497-2\">10.1007/s40120-023-00497-2</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/37289421/?fc=20210216052009&ff=20230608134016&v=2.17.9.post6+86293ac", "published_date": "2023-06-08T10:00:00Z", "source": "PubMed", "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "discovery_date": "2023-06-08T17:40:18.097148Z", "noun_phrases": [ "Treatment", "Cladribine Tablets", "the Management", "Multiple Sclerosis", "the Arabian Gulf", "The CLUE Study" ], "doi": "10.1007/s40120-023-00497-2", "access": "restricted", "takeaways": "Cladribine tablets (CladT) for relapsing multiple sclerosis (RMS) were well-tolerated in the Arabian Gulf.", "categories": [] }, { "article_id": 1391481, "title": "A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry", "summary": "<div><p>Neurodegener Dis Manag. 2023 Jun 7. doi: 10.2217/nmt-2023-0005. Online ahead of print.</p><p><b>ABSTRACT</b></p><p>WHAT IS THIS SUMMARY ABOUT?: Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad<sup>®</sup>) compared with other oral treatments.</p><p>WHAT WERE THE RESULTS?: Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS.</p><p>WHAT DO THE RESULTS MEAN?: The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37287269/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac\">37287269</a> | DOI:<a href=\"https://doi.org/10.2217/nmt-2023-0005\">10.2217/nmt-2023-0005</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/37287269/?fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac", "published_date": "2023-06-08T10:00:00Z", "source": "PubMed", "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "discovery_date": "2023-06-08T10:40:34.732323Z", "noun_phrases": [ "the effectiveness", "cladribine tablets", "other oral treatments", "multiple sclerosis", "the MSBase registry" ], "doi": "10.2217/nmt-2023-0005", "access": "restricted", "takeaways": "The GLIMPSE study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments. People treated with Mavenclad stayed on treatment longer and had fewer relapses.", "categories": [] }, { "article_id": 1391480, "title": "Erratum: Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment", "summary": "<div><p>Noro Psikiyatr Ars. 2023 May 25;60(2):190. doi: 10.29399/npa.28499. eCollection 2023.</p><p><b>ABSTRACT</b></p><p>[This corrects the article on p. 23 in vol. 60, PMID: 36911568.].</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37287556/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac\">37287556</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC10242278/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac\">PMC10242278</a> | DOI:<a href=\"https://doi.org/10.29399/npa.28499\">10.29399/npa.28499</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/37287556/?fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac", "published_date": "2023-06-08T10:00:00Z", "source": "PubMed", "publisher": "Archives of Neuropsychiatry", "container_title": "Archives of Neuropsychiatry", "authors": [ { "url": "http://api.gregory-ms.com/authors/453/", "family_name": "Terzi", "given_name": "Murat", "ORCID": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "discovery_date": "2023-06-08T10:40:30.505847Z", "noun_phrases": [ "Erratum", "Clinical", "Demographic", "Characteristics", "Two-Year Efficacy", "Safety", "Data", "508 Multiple Sclerosis Patients", "Fingolimod Treatment" ], "doi": "10.29399/npa.28499", "access": "open", "takeaways": "", "categories": [] }, { "article_id": 1391479, "title": "Clinical and Demographic Characteristics of Immigrant and Local Multiple Sclerosis Patients in Turkey", "summary": "<div><p>Noro Psikiyatr Ars. 2022 Dec 27;60(2):104-109. doi: 10.29399/npa.28078. eCollection 2023.</p><p><b>ABSTRACT</b></p><p>INTRODUCTION: Increasing migration, due to wars, is one of the environmental factors in the etiology of multiple sclerosis. This study aims to compare demographic and clinical features of immigrant and local MS patients, as well as relapses during pregnancy and postpartum in female patients.</p><p>METHOD: Immigrant (Group 1) and local (Group 2) MS patients were evaluated between January 2019 - September 2020 retrospectively. Below-mentioned data of two groups were recorded and compared: i) demographic data, ii) cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) findings, iii) MS subtypes, iv) expanded disability status scores (EDSS), v) the time between first two relapses, vi) comorbidities, vii) treatment, viii) age of migration and country of origin, ix) pregnancy, x) relapse during pregnancy, xi) birth number, xii) breastfeeding, xiii) postpartum relapses.</p><p>RESULTS: Both of the groups were composed of 34 MS patients (in total n=68). Gender distribution, mean age, MS subtypes, the time between first two relapses, disease duration, EDSS, CSF findings and comorbidities were similar between groups. Symptom of onset was predominantly sensory in both groups. Local patients had more cervical lesions and higher lesion load (p=0.003, p=0.006). 20.6% of migrant MS patients were untreated, all local patients were on treatment. Rates of injection and infusion therapies were similar, the rate of receiving oral therapy was higher in the second group. Clinical features and fertility status of female patients were similar.</p><p>CONCLUSION: According to the study no differences were preseentpresent between immigrant and local MS patients except for MRI lesion load and treatment parameters. The language barrier and irregular follow-ups were the major problems in treatment management.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37287561/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac\">37287561</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC10242286/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac\">PMC10242286</a> | DOI:<a href=\"https://doi.org/10.29399/npa.28078\">10.29399/npa.28078</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/37287561/?fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac", "published_date": "2023-06-08T10:00:00Z", "source": "PubMed", "publisher": "Archives of Neuropsychiatry", "container_title": "Archives of Neuropsychiatry", "authors": [ { "url": "http://api.gregory-ms.com/authors/90060/", "family_name": "PETEK BALCI", "given_name": "Belgin", "ORCID": null }, { "url": "http://api.gregory-ms.com/authors/98123/", "family_name": "BAKIRCIOĞLU DUMAN", "given_name": "Ezgi", "ORCID": null }, { "url": "http://api.gregory-ms.com/authors/98124/", "family_name": "TUNÇ", "given_name": "Cansu", "ORCID": null }, { "url": "http://api.gregory-ms.com/authors/98125/", "family_name": "BAŞTAN TÜZÜN", "given_name": "Birgül", "ORCID": null }, { "url": "http://api.gregory-ms.com/authors/98126/", "family_name": "ÇOKAR", "given_name": "Özlem", "ORCID": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "discovery_date": "2023-06-08T10:40:26.449273Z", "noun_phrases": [ "Immigrant", "Local", "Turkey" ], "doi": "10.29399/npa.28078", "access": "open", "takeaways": "Immigrant and local MS patients were evaluated between January 2019 and September 2020 retrospectively. Both groups were composed of 34 MS patients (n=68). Gender distribution, mean age, MS subtypes, the time between first two relapses, disease duration, EDSS, CSF findings and comorbidities were similar between groups. Local patients had more cervical lesions and higher lesion load. The language barrier and irregular follow-ups were the major problems in treatment management", "categories": [] }, { "article_id": 1391478, "title": "Effectiveness of various diet patterns among patients with multiple sclerosis", "summary": "<div><p>Postep Psychiatr Neurol. 2023 Mar;32(1):49-58. doi: 10.5114/ppn.2023.127246. Epub 2023 May 8.</p><p><b>ABSTRACT</b></p><p>PURPOSE: The main aim of the study was to compare the effectiveness of the dietary patterns studied in the context of multiple sclerosis (MS), including anti-inflammatory, Mediterranean diet (MD), Mediterranean-DASH intervention for neurodegenerative delay (MIND), intermittent fasting (IF), gluten-free and ketogenic diets. In addition, another aim was to verify or otherwise the efficacy of other alternative dietary models, which include the Paleo diet, the Wahls diet, the McDougall diet and the Swank diet. Whether and to what extent the use of different dietary regimens can affect the course and reduction of individual MS symptoms was also examined. The advantages and disadvantages of selected diets and dietary patterns in the context of MS are discussed.</p><p>VIEWS: Autoimmune diseases are estimated to affect more than 3% of the world's people, the majority of whom are of working age. Therefore, delaying the first manifestation of the disease, reducing the number of relapses and alleviating symptoms are particularly welcome developments. In addition to finding effective pharmacotherapy, high hopes for patients lie in nutritional prevention and diet therapy. For years the medical literature has discussed supporting the treatment of diseases caused by an impairment of the body's immune system with the help of nutrition.</p><p>CONCLUSIONS: An appropriate and balanced diet can be extremely helpful in improving the condition and well-being of patients with MS, and effectively support drug therapy.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37287739/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac\">37287739</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC10243296/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac\">PMC10243296</a> | DOI:<a href=\"https://doi.org/10.5114/ppn.2023.127246\">10.5114/ppn.2023.127246</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/37287739/?fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac", "published_date": "2023-06-08T10:00:00Z", "source": "PubMed", "publisher": "Postępy Psychiatrii i Neurologii", "container_title": "Postępy Psychiatrii i Neurologii", "authors": [ { "url": "http://api.gregory-ms.com/authors/88967/", "family_name": "Zielińska", "given_name": "Magdalena", "ORCID": null }, { "url": "http://api.gregory-ms.com/authors/93900/", "family_name": "Michońska", "given_name": "Izabela", "ORCID": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "discovery_date": "2023-06-08T10:40:21.974846Z", "noun_phrases": [ "Effectiveness", "various diet patterns", "patients", "multiple sclerosis" ], "doi": "10.5114/ppn.2023.127246", "access": "open", "takeaways": "An appropriate and balanced diet can be helpful in improving the condition and well-being of patients with MS. Autoimmune diseases affect more than 3% of the world's people.", "categories": [] }, { "article_id": 1391477, "title": "Bruton's tyrosine kinase inhibitors in the treatment of multiple sclerosis", "summary": "<div><p>Postep Psychiatr Neurol. 2023 Mar;32(1):23-30. doi: 10.5114/ppn.2023.126319. Epub 2023 Mar 30.</p><p><b>ABSTRACT</b></p><p>PURPOSE: In this review, we have highlighted a new class of drugs, Bruton's tyrosine kinase (BTK) inhibitors, and summarized the results of recent clinical trials in the treatment of multiple sclerosis.</p><p>VIEWS: Multiple sclerosis (MS) is considered an autoimmune disease of the central nervous system, in which B-lymphocytes and myeloid cells, such as macrophages and microglia, play an important role in the pathogenesis. B-cells induce pathological processes by presenting autoantigens to T-lymphocytes, secreting pro-inflammatory cytokines, and forming ectopic lymphoid follicle-shaped clusters. Accordingly, the activation of microglia contributes to the development of chronic inflammation due to the production of chemokines, cytokines, reactive oxygen, and nitrogen species. BTK is an enzyme important in the activation and function of both B-lymphocytes and microglia. The demand for highly effective and well-tolerated drugs still remains at all stages of MS despite the availability of a number of effective drugs against the disease. Thus, in recent years BTK inhibitors have been the newest approach in the treatment of MS, since they affect the leading links of the pathogenesis of this disease and are able to pass through the blood-brain barrier.</p><p>CONCLUSIONS: The study of new mechanisms of the development of MS continues in combination with the elaboration of new treatment methods, i.e., Bruton's tyrosine kinase inhibitors. The review provided the analysis of core studies evaluating the safety and efficacy of these drugs. In the future, positive results of these studies will be able to greatly expand the therapy for various forms of MS.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37287740/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac\">37287740</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC10243295/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac\">PMC10243295</a> | DOI:<a href=\"https://doi.org/10.5114/ppn.2023.126319\">10.5114/ppn.2023.126319</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/37287740/?fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac", "published_date": "2023-06-08T10:00:00Z", "source": "PubMed", "publisher": "Postępy Psychiatrii i Neurologii", "container_title": "Postępy Psychiatrii i Neurologii", "authors": [ { "url": "http://api.gregory-ms.com/authors/98120/", "family_name": "Shulga", "given_name": "Olga", "ORCID": null }, { "url": "http://api.gregory-ms.com/authors/98121/", "family_name": "Chabanova", "given_name": "Anna", "ORCID": null }, { "url": "http://api.gregory-ms.com/authors/98122/", "family_name": "Kotsiuba", "given_name": "Oleksandra", "ORCID": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "discovery_date": "2023-06-08T10:40:17.558683Z", "noun_phrases": [ "Bruton's tyrosine kinase inhibitors", "the treatment", "multiple sclerosis" ], "doi": "10.5114/ppn.2023.126319", "access": "open", "takeaways": "Bruton's tyrosine kinase (BTK) inhibitors are the newest approach in the treatment of MS. The review provided the analysis of core studies evaluating the safety and efficacy of these drugs.", "categories": [] }, { "article_id": 1391476, "title": "Cognitive and neuropsychiatric endophenotypes in amyotrophic lateral sclerosis", "summary": "<div><p>Brain Commun. 2023 May 19;5(3):fcad166. doi: 10.1093/braincomms/fcad166. eCollection 2023.</p><p><b>ABSTRACT</b></p><p>First- and second-degree relatives of people with amyotrophic lateral sclerosis report higher rates of neuropsychiatric disorders, indicating that risk genes may be pleiotropic, causing multiple phenotypes within kindreds. Such phenotypes may constitute a disease endophenotype that associates with disease liability. We have directly investigated cognitive functioning and neuropsychiatric traits among relatives of people with amyotrophic lateral sclerosis to identify potential endophenotypes of the disease. In a family-based, cross-sectional study design, first- and second-degree relatives of people with amyotrophic lateral sclerosis (<i>n</i> = 149) were compared to controls (<i>n</i> = 60) using an in-depth neuropsychological and neuropsychiatric assessment. Subgroup analyses examined the effect of family history and <i>C9orf72</i> repeat expansion status (<i>n</i> = 16 positive carriers). Relatives of people with amyotrophic lateral sclerosis had lower scores on executive functioning, language and memory tasks compared to controls, with large effect sizes observed on object naming (<i>d</i> = 0.91, <i>P</i> = 0.00001) and phonemic verbal fluency (<i>d</i> = 0.81, <i>P</i> = 0.0003). Relatives also had higher autism quotient attention to detail traits (<i>d</i> = -0.52, <i>P</i> = 0.005), lower conscientiousness (<i>d</i> = 0.57, <i>P</i> = 0.003) and lower openness to experience personality traits (<i>d</i> = 0.54, <i>P</i> = 0.01) than controls. These effects were typically larger in relatives of people with familial, rather than sporadic, amyotrophic lateral sclerosis and were present in both gene carrier and non-carrier relatives of probands with a <i>C9orf72</i> repeat expansion. Poorer phonemic fluency and object naming, along with autism and personality traits, are more frequent in relatives of people with amyotrophic lateral sclerosis. Among kindreds carrying the <i>C9orf72</i> repeat expansion, these traits were identified in relatives regardless of their carrier status, suggesting the presence of a disease-associated endophenotype that is not exclusively mediated by the <i>C9orf72</i> expansion.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37288312/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac\">37288312</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC10243911/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac\">PMC10243911</a> | DOI:<a href=\"https://doi.org/10.1093/braincomms/fcad166\">10.1093/braincomms/fcad166</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/37288312/?fc=20210216052009&ff=20230608064010&v=2.17.9.post6+86293ac", "published_date": "2023-06-08T10:00:00Z", "source": "PubMed", "publisher": "Brain Communications", "container_title": "Brain Communications", "authors": [ { "url": "http://api.gregory-ms.com/authors/4603/", "family_name": "Hardiman", "given_name": "Orla", "ORCID": null }, { "url": "http://api.gregory-ms.com/authors/12028/", "family_name": "Doherty", "given_name": "Mark", "ORCID": null }, { "url": "http://api.gregory-ms.com/authors/12029/", "family_name": "Heverin", "given_name": "Mark", "ORCID": null }, { "url": "http://api.gregory-ms.com/authors/21383/", "family_name": "Pinto-Grau", "given_name": "Marta", "ORCID": "http://orcid.org/0000-0003-0836-6093" }, { "url": "http://api.gregory-ms.com/authors/21392/", "family_name": "Pender", "given_name": "Niall", "ORCID": null }, { "url": "http://api.gregory-ms.com/authors/98113/", "family_name": "Costello", "given_name": "Emmet", "ORCID": "http://orcid.org/0000-0001-8620-9531" }, { "url": "http://api.gregory-ms.com/authors/98114/", "family_name": "Ryan", "given_name": "Marie", "ORCID": null }, { "url": "http://api.gregory-ms.com/authors/98115/", "family_name": "Donohoe", "given_name": "Bronagh", "ORCID": null }, { "url": "http://api.gregory-ms.com/authors/98116/", "family_name": "Kavanagh", "given_name": "Caoimhe", "ORCID": null }, { "url": "http://api.gregory-ms.com/authors/98117/", "family_name": "McLaughlin", "given_name": "Russell Lewis", "ORCID": "http://orcid.org/0000-0003-3915-2135" }, { "url": "http://api.gregory-ms.com/authors/98118/", "family_name": "McHutchison", "given_name": "Caroline", "ORCID": null }, { "url": "http://api.gregory-ms.com/authors/98119/", "family_name": "Abrahams", "given_name": "Sharon", "ORCID": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "discovery_date": "2023-06-08T10:40:12.378175Z", "noun_phrases": [ "Cognitive and neuropsychiatric endophenotypes", "amyotrophic lateral sclerosis" ], "doi": "10.1093/braincomms/fcad166", "access": "open", "takeaways": "First- and second-degree relatives of people with amyotrophic lateral sclerosis report higher rates of neuropsychiatric disorders. They also have lower scores on executive functioning, language and memory tasks compared to controls. Poorer phonemic fluency and object naming, along with autism and personality traits are more frequent in people with the disease.", "categories": [] } ] }